| |
Low risk |
High risk |
| All patients |
| |
ROMA
<13.1% or
<27.7% |
ROMA
<18.04% or <41.6% |
ROMA
≥ 13.1% or ≥ 27.7% |
ROMA
≥ 18.04% or ≥ 41.6% |
| Benign ovarian lesion |
116/131
(88.5%) |
125/131
(95.4%) |
15/131
(11.5%) |
6/131
(4.6%) |
| Ovarian cancer |
10/83
(12%) |
12/83
(14.5%) |
73/83
(88%) |
71/83
(85.5%) |
• FIGO
I and II |
8/22
(36.4%) |
9/22
(40.9%) |
14/22
(63.6%) |
13/22
(59.1%) |
• FIGO
III and IV |
2/61
(3.3%) |
3/61
(4.92%) |
59/61
(96.7%) |
58/61
(95.1%) |
|
• Type I |
8/38
(21.1%) |
9/38
(23.7%) |
30/38
(78.9%) |
29/38
(76.3%) |
|
• Type II |
2/45
(4.4%) |
3/45
(6.67%) |
43/45
(95.6%) |
42/45
(93.3%) |
| Premenopausal patients |
| |
ROMA
<13.1% |
ROMA
<18.04% |
ROMA
≥ 13.1% |
ROMA
≥ 18.04% |
| Benign ovarian lesion |
87/95
(91.6%) |
92/95
(96.8%) |
8/95
(8.4%) |
3/95
(3.2%) |
| Ovarian cancer |
5/21
(23.8%) |
5/21
(23.8%) |
16/21
(76.2%) |
16/21
(76.2%) |
• FIGO
I and II |
4/9
(44.4%) |
4/9
(44.4%) |
5/9
(55.6%) |
5/9
(55.6%) |
• FIGO
III and IV |
1/12
(8.3%) |
1/12
(8.3%) |
11/12
(91.7%) |
11/12
(91.7%) |
|
• Type I |
4/10
(40%) |
4/10
(40%) |
6/10
(60%) |
6/10
(60%) |
|
• Type II |
1/11
(9.1) |
1/11
(9.1) |
10/11
(90.9) |
10/11
(90.9%) |
| Postmenopausal patients |
| |
ROMA
<27.7% |
ROMA
<41.6% |
ROMA
≥ 27.7% |
ROMA
≥ 41.6% |
| Benign ovarian lesion |
29/36
(80.6%) |
33/36
(91.7%) |
7/36
(19.4%) |
3/36
(8.3%) |
| Ovarian cancer |
5/62
(8.1%) |
7/62
(11.3%) |
57/62
(91.9%) |
55/62
(88.7%) |
• FIGO
I and II |
4/13
(30.8%) |
5/13
(38.5%) |
9/13
(69.2%) |
8/13
(61.5%) |
• FIGO
III and IV |
1/49
(2%) |
2/49
(4.1%) |
48/49
(98%) |
47/49
(95.9%) |
|
• Type I |
4/28
(14.3%) |
5/28
(17.9%) |
24/28
(85.7%) |
23/28
(82.1%) |
|
• Type II |
1/34
(2.9) |
2/34
(97.1) |
33/34
(97.1) |
32/34
(94.1) |
|
